đď¸ AbbVie Q1 2025 Earnings â Immunology Momentum, Raised Guidance, and Strategic Growth Movesđ
Earning Release: April 25, 2025đ Sources: AbbVie Q1 2025 Earnings Release, Investor Charts, and Call TranscriptIn this episode, we break down AbbVieâs strong Q1 2025 results, pipeline updates, and future growth strategy beyond Humira.đ Quarterly Highlights⢠Revenue: $13.3B (+8.4% YoY reported, +9.8% operational)⢠Adjusted EPS: $2.46 (+6.5% YoY), beating guidance midpoint⢠Raised full-year 2025 guidance: EPS now $12.09â$12.29, revenue forecast up $700M to ~$59.7Bđ Portfolio Performance⢠Immunology: Skyrizi (+70.5% YoY) and Rinvoq (+57.2% YoY) delivered combined $5.1B sales, offsetting Humiraâs -50.6% decline⢠Neuroscience: Strong growth from Vraylar, Botox Therapeutic, and migraine portfolio (Ubrelvy, Qulipta)⢠Oncology: Solid contributions from Venclexta and Elahere despite Imbruvica erosion⢠Aesthetics: Revenue decline (-11.7% YoY) due to economic headwinds; long-term growth potential remainsđ Pipeline and Strategic Investments⢠Obesity: New amylin analog program (ABBV-295) shows early promise⢠Oncology: Partnerships with Xilio and Nimble Therapeutics⢠Neuroscience: Positive Phase 3 data for Tavapadon in Parkinson's disease⢠Aesthetics: Submitted new fast-acting BoNT/E toxin for FDA approvalđ Manufacturing and Tariff Readiness⢠Over $10B planned U.S. manufacturing investment over next decade⢠Strengthens resilience against potential pharmaceutical sector tariffsđŽ Management Outlook⢠Clear growth runway through at least 2029 with a high single-digit revenue CAGR⢠Continued investment focus across Immunology, Neuroscience, Oncology, Aesthetics, and now ObesityAbbVie is executing well on its post-Humira transformation â with strong portfolio momentum, expanding pipelines, and strategic initiatives driving future growth.#AbbVie #Earnings #Pharma #Biotech #Immunology #InvestingPodcast